WO2008073351A3 - Uses of cerberus, coco and derivatives thereof - Google Patents

Uses of cerberus, coco and derivatives thereof Download PDF

Info

Publication number
WO2008073351A3
WO2008073351A3 PCT/US2007/025180 US2007025180W WO2008073351A3 WO 2008073351 A3 WO2008073351 A3 WO 2008073351A3 US 2007025180 W US2007025180 W US 2007025180W WO 2008073351 A3 WO2008073351 A3 WO 2008073351A3
Authority
WO
WIPO (PCT)
Prior art keywords
cerberus
coco
derivatives
myostatin
gdf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/025180
Other languages
French (fr)
Other versions
WO2008073351A9 (en
WO2008073351A2 (en
Inventor
Asya Grinberg
John Knopf
Ravindra Kumar
Jasbir Seehra
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Acceleron Pharma Inc
Original Assignee
Acceleron Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acceleron Pharma Inc filed Critical Acceleron Pharma Inc
Priority to CA002671983A priority Critical patent/CA2671983A1/en
Priority to EP07862679A priority patent/EP2099471A2/en
Priority to AU2007332819A priority patent/AU2007332819A1/en
Priority to JP2009540329A priority patent/JP2010512326A/en
Publication of WO2008073351A2 publication Critical patent/WO2008073351A2/en
Publication of WO2008073351A3 publication Critical patent/WO2008073351A3/en
Anticipated expiration legal-status Critical
Publication of WO2008073351A9 publication Critical patent/WO2008073351A9/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)

Abstract

The disclosure relates to Cerberus/Coco polypeptides or variants thereof for use in treating a variety of disorders associated with myostatin, nodal and GDF-11.
PCT/US2007/025180 2006-12-08 2007-12-10 Uses of cerberus, coco and derivatives thereof Ceased WO2008073351A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002671983A CA2671983A1 (en) 2006-12-08 2007-12-10 Uses of cerberus, coco and derivatives thereof
EP07862679A EP2099471A2 (en) 2006-12-08 2007-12-10 Uses of cerberus, coco and derivatives thereof
AU2007332819A AU2007332819A1 (en) 2006-12-08 2007-12-10 Uses of cerberus, coco and derivatives thereof
JP2009540329A JP2010512326A (en) 2006-12-08 2007-12-10 Use of Cerberus, Coco and their derivatives

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US87393306P 2006-12-08 2006-12-08
US60/873,933 2006-12-08

Publications (3)

Publication Number Publication Date
WO2008073351A2 WO2008073351A2 (en) 2008-06-19
WO2008073351A3 true WO2008073351A3 (en) 2008-11-27
WO2008073351A9 WO2008073351A9 (en) 2020-07-09

Family

ID=39183158

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/025180 Ceased WO2008073351A2 (en) 2006-12-08 2007-12-10 Uses of cerberus, coco and derivatives thereof

Country Status (6)

Country Link
US (2) US7833971B2 (en)
EP (1) EP2099471A2 (en)
JP (1) JP2010512326A (en)
AU (1) AU2007332819A1 (en)
CA (1) CA2671983A1 (en)
WO (1) WO2008073351A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9045553B2 (en) * 2004-05-27 2015-06-02 Acceleron Pharma, Inc. Cerberus/Coco derivatives and uses thereof
MA41919A (en) 2015-04-06 2018-02-13 Acceleron Pharma Inc ALK4 HETEROMULTIMERS: ACTRIIB AND THEIR USES
US10227392B2 (en) 2015-04-06 2019-03-12 Acceleron Pharma Inc. ALK7:ActRIIB heteromultimers and uses thereof
WO2017177013A1 (en) 2016-04-06 2017-10-12 Acceleron Pharma Inc. Alk7 antagonists and uses thereof
HRP20210694T1 (en) 2016-07-15 2021-09-17 Acceleron Pharma, Inc. PREPARATIONS CONTAINING ACTRIIA POLYPEPTIDES FOR USE FOR THE TREATMENT OF PULMONARY HYPERTENSION
BR112019006993A2 (en) 2016-10-05 2019-09-03 Acceleron Pharma Inc alk4 heteromultimers: actriib and uses thereof
EP4142769A4 (en) 2020-04-28 2024-05-15 Acceleron Pharma Inc. ACTRII PROTEINS AND THEIR USE IN THE TREATMENT OF POST-CAPILLARY PULMONARY HYPERTENSION
US12508262B2 (en) 2020-04-30 2025-12-30 Keros Therapeutics, Inc. Methods of using ALK2 inhibitors
WO2022098812A1 (en) 2020-11-04 2022-05-12 Keros Therapeutics, Inc. Methods of treating iron overload

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999001553A1 (en) * 1997-07-03 1999-01-14 Genetics Institute, Inc. Murine and human cerberus-like proteins and compositions comprising them
US6610510B1 (en) * 1997-04-29 2003-08-26 Regeneron Pharmaceuticals, Inc. Morphogenic proteins
WO2005115439A2 (en) * 2004-05-27 2005-12-08 Acceleron Pharma Inc. Cerberus/coco derivatives and uses thereof

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6133232A (en) * 1996-06-20 2000-10-17 The Regents Of The University Of California Endoderm, cardiac and neural inducing factors
WO1998034951A1 (en) 1997-02-11 1998-08-13 Amrad Operations Pty. Ltd. A new cytokine family and uses thereof
US6656475B1 (en) 1997-08-01 2003-12-02 The Johns Hopkins University School Of Medicine Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same
WO1999040181A1 (en) 1998-02-05 1999-08-12 The Johns Hopkins University School Of Medicine Growth differentiation factor-8
US20040009535A1 (en) 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
AU3511100A (en) 1999-03-12 2000-10-04 Regeneron Pharmaceuticals, Inc. Novel nucleic acids and polypeptides
WO2002032929A2 (en) 2000-10-19 2002-04-25 Genaissance Pharmaceuticals, Inc. Haplotypes of the cer1 gene
AU2002243495A1 (en) 2001-01-12 2002-07-24 University Of Medicine And Dentistry Of New Jersey Bone morphogenetic protein-2 in the treatment and diagnosis of cancer
EP1383867A2 (en) 2001-03-23 2004-01-28 Axordia Limited Stem cell differentiation
AU2002303219A1 (en) 2001-03-30 2002-10-15 Corixa Corporation Compositions and methods for the therapy and diagnosis of cancer
GB0111004D0 (en) 2001-05-04 2001-06-27 Univ Sheffield Screening method
GB0118223D0 (en) 2001-07-26 2001-09-19 Univ Sheffield Stem loop RNA
KR101072867B1 (en) 2001-10-31 2011-10-17 유니버시티 오브 노스 텍사스 헬스 사이언스 센터 Bone morphogenic proteins (bmp), bmp receptors and bmp binding proteins and their use in the diagnosis and treatment of glaucoma
GB0130738D0 (en) * 2001-12-21 2002-02-06 Serono Internat S A Protein
US20030134790A1 (en) * 2002-01-11 2003-07-17 University Of Medicine And Dentistry Of New Jersey Bone Morphogenetic Protein-2 And Bone Morphogenetic Protein-4 In The Treatment And Diagnosis Of Cancer
BR0307871A (en) 2002-02-21 2005-04-12 Wyeth Corp Folistatin Domain-Containing Proteins
US7193069B2 (en) * 2002-03-22 2007-03-20 Research Association For Biotechnology Full-length cDNA
US20030194704A1 (en) * 2002-04-03 2003-10-16 Penn Sharron Gaynor Human genome-derived single exon nucleic acid probes useful for gene expression analysis two
US20040023356A1 (en) 2002-06-14 2004-02-05 Robb Krumlauf Wise/Sost nucleic acid sequences and amino acid sequences
CN101287484B (en) * 2002-12-20 2012-10-10 安姆根有限公司 Binding agents that inhibit myostatin
WO2004074460A2 (en) 2003-02-19 2004-09-02 The Rockefeller University Nucleotide and protein sequences of coc genes and methods based thereon
KR100543937B1 (en) * 2003-10-31 2006-01-23 주식회사 하이닉스반도체 Data output control circuit

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6610510B1 (en) * 1997-04-29 2003-08-26 Regeneron Pharmaceuticals, Inc. Morphogenic proteins
WO1999001553A1 (en) * 1997-07-03 1999-01-14 Genetics Institute, Inc. Murine and human cerberus-like proteins and compositions comprising them
WO2005115439A2 (en) * 2004-05-27 2005-12-08 Acceleron Pharma Inc. Cerberus/coco derivatives and uses thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
AVSIAN-KRETCHMER ORNA ET AL: "Comparative genomic analysis of the eight-membered ring cystine knot-containing bone morphogenetic protein antagonists.", MOLECULAR ENDOCRINOLOGY (BALTIMORE, MD.) JAN 2004, vol. 18, no. 1, January 2004 (2004-01-01), pages 1 - 12, XP002488397, ISSN: 0888-8809 *
YANAGITA M: "BMP antagonists: Their roles in development and involvement in pathophysiology", CYTOKINE AND GROWTH FACTOR REVIEWS, OXFORD, GB, vol. 16, no. 3, 1 June 2005 (2005-06-01), pages 309 - 317, XP004964511, ISSN: 1359-6101 *

Also Published As

Publication number Publication date
AU2007332819A1 (en) 2008-06-19
US8796199B2 (en) 2014-08-05
CA2671983A1 (en) 2009-06-19
WO2008073351A9 (en) 2020-07-09
US7833971B2 (en) 2010-11-16
US20110046057A1 (en) 2011-02-24
EP2099471A2 (en) 2009-09-16
WO2008073351A2 (en) 2008-06-19
US20090082270A1 (en) 2009-03-26
JP2010512326A (en) 2010-04-22

Similar Documents

Publication Publication Date Title
WO2008073351A3 (en) Uses of cerberus, coco and derivatives thereof
WO2005115439A3 (en) Cerberus/coco derivatives and uses thereof
EP2175050B8 (en) Nozzle for cold spray, and cold spray device using the nozzle for cold spray
CA111635S (en) Bottle
IL186090A0 (en) Cgrp antagonists, method for the production thereof, and their use as medicaments
CA118619S (en) Hinged container
EP1732917B8 (en) Selected cgrp antagonists, methods for the production thereof and their use as medicaments
WO2010060937A3 (en) Pharmaceutical combination comprising a hsp 90 inhibitor and a mtor inhibitor
ZA200800431B (en) Selected cgrp antagonists, methods for the production thereof and their use as medicaments
PL2463302T3 (en) Multivalent immunoglobulins modified in the structural loop region
DE602006015981D1 (en) SOUND DISPENSING MEMBRANE, ELECTRONIC COMPONENT WITH SOUND DISPENSING MEMBRANE AND PROCESS APPLIED TO THE MANUFACTURING COMPONENT
IL181012A0 (en) Substituted 8-aminoalkoxi-xanthines, method for the production thereof and use thereof as medicaments
CA118314S (en) Dispensing pump head
CA120345S (en) Dispensing device for dishwashers
WO2009071689A3 (en) 5-halogen-substituted oxindole derivatives and use thereof for treating vasopressine-dependent diseases
IL189497A0 (en) Selected cgrp antagonists, methods for the production thereof and their use as medicaments
ZA200808754B (en) Tetrahydronaphthaline derivatives, methods for the production and use hereof as anti-inflammatory agents
CA120350S (en) Dispensing device for dishwashers
IL199168A0 (en) Indolizine derivatives and the use thereof as antidiabetics
EP2025667A4 (en) 9,10-secopregnane derivative and pharmaceutical
GB2422393B (en) Safety valve for use in an injection well
EP2266619A4 (en) Pharmaceutical composition based on hepatoprotector and prebiotic, the production and use thereof
EP2062652A4 (en) Spray device and process for manufacturing the same
IL195869A0 (en) Phenylpentadienoyl derivatives and their use as par 1 antagonists
PL1934039T3 (en) Stable fiber laminate, and method and device for the production thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07862679

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2009540329

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2671983

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2007332819

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2007862679

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2007332819

Country of ref document: AU

Date of ref document: 20071210

Kind code of ref document: A